PubMed Health⌕ Search

Biomedical subjects

J C de Jong

Publications and source records attributed to J C de Jong.

At least 19 recordsLinked to original sources
PubMed1999

[Influenza pandemics: past and future].

The circulation of numerous influenza virus subtypes in water birds constitutes a continuous threat with respect to emergence of a future influenza pandemic. The interspecies barrier is high but has already been breached 3 times this century, notably in 1918, 1957 and 1968. Still, it is impossible to predict when another pandemic will occur. Continuous and intensive surveillance of influenza viruses in man, pigs, and birds, especially in China, may provide the opportunity to prepare a vaccine timely in sufficient amounts, at least for the industrialised countries.

Animals↗
PubMed1999

[Influenza season 1998/99; composition of vaccine for 1999/2000].

The first indication of influenza activity in the Netherlands in the 1998/'99 season was the isolation of an influenza B virus in week 47 of 1998. In subsequent weeks influenza activity slowly increased, reaching a peak in week 6 of 1999. After a gradual decline for three weeks a second peak was reached in week 8 of 1999. The first wave of influenza activity was primarily caused by influenza B viruses, whereas during the second wave predominantly influenza A viruses of the A/H3N2 subtype were isolated. The antigenic properties of the influenza A viruses resembled those of the viruses isolated in the previous season and the vaccine strain A/Sydney/5/97. The influenza B viruses did not completely match with B/Harbin/7/94 which is most commonly used for vaccine production. The vaccine, however, did provide good protection against the epidemic strains of influenza. This season influenza A/H1N1 viruses did not play a significant part and only a small number of viruses of this subtype were isolated at the end of the season. For the influenza season 1999/2000 it is recommended by the World Health Organization that the vaccines contain the following (or similar) virus strains: A/Sydney/5/97 (H3N2), A/Beijing/262/95 (H1N1) and B/Beijing/184/93.

Guidelines as Topic↗
PubMed1999

Influenza virus subtype cross-reactivities of haemagglutination inhibiting and virus neutralising serum antibodies induced by infection or vaccination with an ISCOM-based vaccine.

In order to study the levels of cross-reactivity of the influenza virus-specific antibody response upon infection or vaccination, usually hemagglutination inhibition assays are performed. In the present study post-infection ferret sera and serum samples obtained from cynomolgus macaques which were vaccinated with an ISCOM preparation based on the influenza virus strain A/Netherlands/18/94 (H3N2) were analyzed for cross-reactivity in the hemagglutination inhibition assay and in virus neutralization assays. It was shown that the cross-reactivity of the antibodies induced upon vaccination or infection with influenza virus proved to be more limited in the virus neutralization assay than in the hemagglutination assay. The strong antibody response induced by vaccination with the A/Netherlands/18/94-ISCOM preparation was shown to be cross-reactive with recent influenza virus strains, which were isolated since 1992, but not with older strains.

Adjuvants, Immunologic↗
PubMed1999

A straightforward synthetic approach for roxindole.

A concise synthetic approach to the dopamine autoreceptor agonist roxindole 1 has been devised. The key step in the novel route is the addition of succinic anhydride to 5-methoxyindolylmagnesium bromide, which circumvents the cumbersome construction of the indole moiety - via the Japp Klingemann- Fischer indole methodology - in the original route. This novel route will enable a quick, multi-gram synthesis of roxindole from cheap starting materials.

Dopamine Agonists↗
PubMed1999

ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus.

Recently avian influenza A viruses of the H5N1 subtype were shown to infect humans in the Hong Kong area, resulting in the death of six people. Although these viruses did not efficiently spread amongst humans, these events illustrated that influenza viruses of subtypes not previously detected in humans could be at the basis of a new pandemic. In the light of this pandemic threat we evaluated and compared the efficacy of a classical non-adjuvanted subunit vaccine and a vaccine based on immune stimulating complexes (ISCOM) prepared with the membrane glycoproteins of the human influenza virus A/Hong Kong 156/97 (H5N1) to protect roosters against a lethal challenge with this virus. The ISCOM vaccine induced protective immunity against the challenge infection whereas the non-adjuvanted subunit vaccine proved to be poorly immunogenic and failed to induce protection in this model.

Adjuvants, Immunologic↗
PubMed1999

Antigenic drift in swine influenza H3 haemagglutinins with implications for vaccination policy.

In order to explore the occurrence of antigenic drift in swine influenza A(H3N2) virus, we examined virus strains from outbreaks of respiratory disease among finishing pigs in the Netherlands in 1996 and 1997 and from earlier outbreaks. In contrast to swine H3N2 strains from the 1980s, the recent isolates did not show significant cross-reactivity with human influenza A(H3N2) viruses from 1972-1975 in haemagglutination inhibition tests. These new strains form a separate branch in the phylogenetic trec of the HA1 parts of HA. We conclude that recently there has been considerable antigenic drift within the swine H3N2 viruses in the Netherlands and Belgium and recommend replacement of the A/Port Chalmers/1/73 (H3N2) strain in the current vaccine by a more recent swine H3N2 isolate.

Animals↗
PubMed1999

The duration and magnitude of influenza epidemics: a study of surveillance data from sentinel general practices in England, Wales and the Netherlands.

Weekly incidence data for influenza-like illness, routinely collected in sentinel general practices in England and Wales and in the Netherlands over 10 winter periods (week 37 in one year to week 20 in the next, 1987/1988-1996/1997) were examined in conjunction with matching virus isolate data to define epidemic periods of influenza in the two countries. We first defined the background rates of recording influenza-like illness which occurred at times when only sporadic or no isolations of virus were reported. The background rates were similar in the two networks with mean weekly incidence in England and Wales of 28.1 per 100,000 (all ages) and in the Netherlands 29.8. Epidemic periods defined as lying above the upper 95% confidence level of the background rate lasted on an average of about 10 weeks. Once epidemics were recognised, peak incidence was generally achieved within 4 weeks. The excess population (all ages) consulting general practitioners during influenza epidemic periods was calculated from the difference between the observed and background incidence rates, and expressed as a percentage of the total population. In the 10 periods surveyed, the percentage of the population consulting and diagnosed with influenza-like illness in England and Wales ranged from 0.4% in 1991/1992 to 1.7% in 1989/1990 and in the Netherlands from 0.5% in 1990/ 1991 to 2.1% in 1989/1990. The duration and epidemic periods were broadly similar in the two countries though the excess consulting population during the 10 epidemics studied averaged 0.85% in England and Wales compared with 1.39% in the Netherlands. There were substantial differences between the two countries in the impact of influenza in individual years, as measured in the consulting population even though the predominant virus (sub)types were similar.

Disease Outbreaks↗
PubMed1999

Improved detection of rhinoviruses in clinical samples by using a newly developed nested reverse transcription-PCR assay.

This paper describes the development and evaluation of a new nested reverse transcription (RT)-PCR for the detection of rhinovirus in clinical samples. The nucleotide sequences of the 5' noncoding regions of 39 rhinoviruses were determined in order to map the most conserved subregions. We designed a set of rhinovirus-specific primers and probes directed to these subregions and developed a new nested RT-PCR. The new assay includes an optimal RNA extraction method and amplicon identification with probe hybridization to discriminate between rhinoviruses and the closely related enteroviruses. It proved to be highly sensitive and specific. When tested on a dilution series of cultured viruses, the new PCR protocol scored positive at 10- to 100-fold-higher dilutions than a previously used nested RT-PCR. When tested on a collection of clinical samples obtained from 1,070 acute respiratory disease patients who had consulted their general practitioners, the new assay demonstrated a rhinovirus in 24% of the specimens, including all culture-positive samples, whereas the previously used PCR assay or virus culture detected a rhinovirus in only 3.5 to 6% of the samples. This new assay should help determine the disease burden associated with rhinovirus infections.

Base Sequence↗
PubMed1998

[The influenza season 1997/'98 and the vaccine composition for 1998/'99].

The 1997/'98 influenza season in the Netherlands was marked by influenza A/H3N2 activity which never reached a true epidemic level. There was no real peak activity either but a prolonged period of increased activity of approximately eight weeks with a maximum in week 13, when sentinel physicians reported 16.6 cases of influenza-like illness per 10,000 inhabitants. It was not until week 18 of 1998 that the influenza activity declined to baseline levels. During the season, almost exclusively influenza A/H3N2 viruses were isolated, of which the majority resembled the new strain influenza A/Sydney/5/97 (H3N2). Further analysis of these variant viruses revealed that, although there was some cross-reactivity with the vaccine strain (A/Nanchang/933/95), no optimal protection could be expected to be induced by the vaccine. Antigenic characterisation of the sporadic influenza A/H1N1 and influenza B viruses showed that these were related to the vaccine strains. As a result of these findings, the World Health Organization (WHO) recommended to change the H3N2 strain in the influenza vaccine for the season 1998/'99 to an influenza A/Sydney/5/97(H3N2)-like strain. Based on epidemiological data from other countries, it was also decided to change the influenza A/H1N1 component to an influenza A/Beijing/262/95 (H1N1)-like strain.

Disease Outbreaks↗
PubMed1998

[Influenza A (H5N1) in Hong Kong: Forerunner of a pandemic or just a scientifically interesting phenomenon and a useful exercise in pandemiology?].

In 1997, 18 influenza patients were detected who were infected with influenza A(H5N1) virus. Six patients died. Presumably most of the patients had acquired the infection directly from chickens with the fowl plague prevalent in China in 1997. These are the first reported cases of isolation of influenza viruses belonging to one of the H4-H15 subtypes from human influenza patients. Man-to-man transmission of the virus has not been demonstrated but cannot be excluded in every case. Genetic analyses of seven of these virus isolates showed that no reassortment with a human or porcine influenza virus had occurred. It is unpredictable whether the H5N1-virus in question will start a pandemic in the next few years.

Adolescent↗
PubMed1998

[Influenza A(H5N1) in Hong Kong: forerunner of a pandemic or an only scientifically interesting phenomenon and a useful exercise in pandemiology?].

From a three-year old boy in Hong Kong who died in May 1997 with an extensive influenza pneumonia an influenza A virus has been isolated which was, first at the National Influenza Centre of the Netherlands, identified as belonging to subtype H5N1. Presumably the patient had acquired the infection directly from an outbreak of fowl plague among chickens. As far as is known this is the first case of the isolation of an influenza virus belonging to one of the subtypes H4-H15 from a human influenza patient. At the end of 1997 seventeen more cases of human A (H5N1) influenza have been detected in Hong Kong, including five fatal cases. Genetic analyses of seven of these virus isolates did not reveal the occurrence of reassortment with a human or porcine influenza virus, which could have rendered the virus potentially pandemic. Man-to-man transmission of the virus has not been demonstrated but cannot be excluded either. This event has shown that the WHO surveillance of influenza viruses, although perhaps not perfect, has functioned well.

Animals↗
PubMed1997

[Influenza in the 1996/'97 season; vaccine composition for the 1997/'98 season].

The first indication of flu activity in the Netherlands in the 1996/'97 season was the isolation of an A/H3N2 influenza virus in week 48 of 1996. In subsequent weeks influenza viruses were isolated sporadically. The clinical influenza activity increased from week I of 1997 and reached its peak in week 4 of 1997. Simultaneously with the increase of clinical influenza activity, an increasing number of influenza viruses were isolated. The epidemic had a relatively small extent. Initially, A/H3N2 influenza viruses were predominant, but in the second half of the epidemic an increasing number of influenza B viruses were isolated as well. The A/H3N2 viruses were antigenically fairly strongly distinct from the variants prevalent in the preceding years. This season influenza A/HINI viruses did not play a significant role and only one virus of this subtype was isolated. All influenza A/H3N2, A/HINI and B viruses isolated were antigenically similar to the vaccine strains.

Adolescent↗
PubMed1996

[Influenza in the 1995/'96 season; vaccine composition for the 1996/'97 season].

The 1995/'96 season in the Netherlands was marked by an influenza A/H3N2 epidemic that peaked in week 5I. In this week, 39 patients with influenza-like illness per 10,000 inhabitants contacted the sentinel physicians. With two exceptions, influenza A/H3N2 viruses exclusively were isolated during this epidemic period. In the first few months of 1996, a substantial number of influenza A/H1N1 and influenza B viruses were isolated as well. Serological characterization of the circulating viruses revealed that they all resembled the virus strains of the influenza vaccine of 1995/'96, which therefore probably will have provided good protection. Based on the epidemiological data from other countries and the fact that similar H3N2 viruses have been circulating since 1993, the World Health Organization has recommended to exchange the H3N2 component of the 1996/'97 vaccine for a Wuhan/353/95 (H3N2)-like strain.

Humans↗
PubMed1995

[Influenza in the 1994/95 season; composition of vaccine for the 1995/96 season].

The 1994/'95 season in the Netherlands was marked by a limited influenza activity which only emerged in late February. The influenza activity remained elevated until the end of April, which is unusually late, and epidemic activity was only reported in the south of the country. Both influenza A/H3N2 and B viruses were isolated in this period. In addition, influenza A/HINI viruses were isolated for the first time since March 1993, from two patients. The majority of the influenza A strains that circulated in the Netherlands in 1994/'95 reacted well with ferret antiserum raised against the strains of the 1994/'95 influenza vaccine, which therefore probably offered good protection. The reactivity of the B strains to antiserum raised against the vaccine strain, B/Panama/45/90, was only moderate, which implies that the protection against the Dutch influenza B strains was not optimal. Based on the results of the worldwide influenza surveillance, the World Health Organization (WHO) has recommended an alteration in both the A/H3N2 and the B component for the vaccine of 1995/1996.

Disease Outbreaks↗